Key result
RCT protocol compares single liposomal bupivacaine to continuous standard bupivacaine for proximal humerus fracture pain.
Why the study?
Continuous ISB nerve blocks prolong postoperative analgesia after proximal humerus fracture fixation but present technical and catheter-related complications, and the analgesic efficacy of single-injection liposomal bupivacaine versus continuous standard bupivacaine infusion has not been investigated.
RCT (n=78)
Double-blind
No
Answers are grounded in this paper and cite their sources.
Interscalene brachial plexus nerve blocks (ISB) are commonly used to reduce postoperative pain for proximal humerus fracture fixation. Good pain control minimizes opioid consumption, facilitates mobilization and enhances functional recovery. While ISB continuous nerve block infusion can prolong postoperative analgesia, it is technically demanding and associated with problems such as catheter displacement and obstruction. Liposomal bupivacaine allows prolonged duration of analgesia up to 72 hours after single injection. Single ISB injection using liposomal bupivacaine can perhaps provide extended pain relief without the potential problems associated with continuous nerve catheters. The analgesic efficacy of single injection of liposomal bupivacaine versus continuous nerve infusion with standard bupivacaine has not been investigated. In this study protocol, we describe a single centre, double blind, non-inferiority randomized controlled trial to compare the analgesic effect of single ISB injection using liposomal bupivacaine (LP-ISB group) versus continuous ISB nerve infusion using standard bupivacaine (C-ISB) after proximal humeral fracture fixation. Seventy-eight patients will be recruited after obtaining informed consent. Patients in the LP-ISB group will receive ISB injection with 10ml of 1.33% liposomal bupivacaine, followed by nerve catheter infusion using normal saline at 5ml/hr. Patients in the C-ISB group will receive ISB injection with 10ml of 0.25% standard bupivacaine, followed by nerve catheter infusion with 0.2% standard bupivacaine at 5ml/hr. All patients will receive the same perioperative general anaesthetic and analgesic management. The primary outcome is the weighted AUC NRS pain score (scale 0-10) at rest and with movement during the acute postoperative period. Secondary outcomes in the acute postoperative period include postoperative opioid consumption, overall analgesic benefit score and adverse effects. Longer-term secondary outcomes that will be assessed include health related quality of life, upper limb functional scores (QuickDASH) and chronic pain. This clinical study has been registered at ClinicalTrials.gov (NCT04928664).
No takes yet. Share an insight, caveat, or question.
Chan et al. (2023) conducted an RCT in Proximal humerus fracture (n=78). Liposomal bupivacaine vs. Standard bupivacaine (10ml of 0.25% injection followed by 0.2% infusion at 5ml/hr) was evaluated on Weighted AUC NRS pain score (scale 0-10) at rest and with movement during the acute postoperative period. This study protocol outlines a non-inferiority RCT comparing single liposomal bupivacaine injection versus continuous standard bupivacaine for pain after proximal humerus fracture fixation.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: